Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data

摘要: SUMMARY  The continuum of care for patients with metastatic colorectal cancer continues to evolve as data from clinical trials evaluating novel agents, treatment combinations or sequencing become available. concept continued angiogenesis suppression through multiple lines therapy has been hypothesized be beneficial in terms increased overall survival. This evaluated trials, suggesting that exposure bevacizumab the first-line setting and beyond first disease progression was associated statistically significant improvements survival outcomes. Here, we will discuss context recent bevacizumab, other antiangiogenic agents targeted therapies first- later-line settings.